Bydgoszcz

• VERDICT - Optimal Treatment Target in Active Ulcerative Colitis (UC) Ended
  2024-514183-21-00 6 2021-01-15 Ulcerative colitis
• TSRO-Ph2, Dostarlimab +CT vs Pembro +CT, 1L H2H efficacy comparison in Metastatic NSCLC pts. PERLA Ended
  2023-505894-33-00 4 2020-11-25 Lung Cancer, Non-Small Cell
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended
  2024-514495-41-00 5 2020-11-04 Primary Progressive Multiple Sclerosis
• A Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination with Cabozantinib Versus Cabozantinib Alone in Patients wit … Ended
  2024-517785-42-00 5 2020-10-08 Renal cell carcinoma (RCC)
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease Ended
  2023-507303-55-00 4 2020-09-30 Alzheimer Disease
• Double-blind (neither the patient nor the doctor knows treatment allocation of the patient), randomized, placebo-controlled, prospective pha … Ended
  2023-509737-39-00 5 2020-08-19 Primary infection prophylaxis in patients with chronic lymphocytic leu
• An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from fumarate-based RMS approv … Ended
  2023-507493-41-00 5 2020-08-04 relapsing multiple sclerosis (RMS)
• Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide plus ADT in mHSPC Ended
  2023-507024-24-00 5 2020-05-05 Metastatic hormone sensitive prostate cancer
• An extension study to learn about the long-term safety of fenfluramine hydrochloride for seizures in children and adults with rare seizure d … Ended
  2024-515680-61-00 5 2020-02-07 Dravet syndrome or Lennox-Gastaut syndrome
• Ertugliflozin Pediatric Study Ended
  2022-501085-21-00 5 2019-11-29 Type 2 Diabetes Mellitus
• A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery Ended
  2022-502886-71-00 5 2019-11-20 Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA N
• An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertensi … Ended
  2023-504601-36-00 5 2019-11-20 Open-angle Glaucoma
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• Phase 3b/4 Study in Rheumatoid Arthritis Ended
  2023-508022-10-00 6 2019-07-25 Rheumatoid Arthritis
• Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC Ended
  2022-500413-11-00 5 2019-06-17 Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC)
• A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli … Ended
  2022-501970-20-01 5 2019-06-07 Cis-eligible Muscle-invasive bladder cancer.
• Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus Ended
  2022-502444-13-00 4 2019-05-28 Systemic Lupus Erythematosus
• A Phase IB Study to determine efficacy and safety of Durvalumab and/or novel anti-cancer agents, with or without chemotherapy, in patients w … Ended
  2024-511956-42-00 3 2019-05-14 Metastatic Non-Small Cell Lung Cancer (NSCLC)
• Acute-On-Chronic Liver Failure (ACLF) at High Risk of Hospital Mortality Ended
  2022-502187-20-00 5 2019-04-11 Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected eith
• Clinical Trial conduct to investigate if Daratumumab therapy for multiple myeloma patients with minimal residual disease (MRD) reappearance … Ended
  2024-518400-50-00 4 2018-11-14 Multiple Myeloma and Minimal Residual Disease
• A study that allows patients from previous studies to continue on the medication. The aim of the study is to determine how safe and effectiv … Ended
  2023-508955-37-00 5 2018-10-10 Moderate to severe atopic dermatitis
• A Study Evaluating the Safety and Efficacy of KTE-X19 in pediatric and adolescent Subjects with Relapsed/Refractory B-precursor Acute Lympho … Ended
  2023-509440-97-00 3 2018-09-25 Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
• A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la … Ended
  2023-506543-41-00 5 2018-07-25 Multiple sclerosis (MS)
• Study of durvalumab/placebo + chemoradiation therapy in Patients with Unresectable, Locally Advanced Non-small Cell Lung Cancer Ended
  2024-515321-29-00 5 2018-06-26 Patients with Locally Advanced, Unresectable Non-small Cell Lung Cance

Showing 673–696 of 707 trials